# 24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion

> **NCT02361242** · PHASE2 · COMPLETED · sponsor: **Pharnext S.C.A.** · enrollment: 45 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** PXT00864

## Key facts

- **NCT ID:** NCT02361242
- **Lead sponsor:** Pharnext S.C.A.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2016-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02361242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02361242, "24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02361242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*